KR960028907A - 암환자를 치료하기 위한 세트랄린의 용도 - Google Patents

암환자를 치료하기 위한 세트랄린의 용도 Download PDF

Info

Publication number
KR960028907A
KR960028907A KR1019960000735A KR19960000735A KR960028907A KR 960028907 A KR960028907 A KR 960028907A KR 1019960000735 A KR1019960000735 A KR 1019960000735A KR 19960000735 A KR19960000735 A KR 19960000735A KR 960028907 A KR960028907 A KR 960028907A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
administered
cancer
composition according
patient diagnosed
Prior art date
Application number
KR1019960000735A
Other languages
English (en)
Inventor
에밀 에띠엔느 삐에르
색톤 크래이그
Original Assignee
알렌 제이. 스피겔
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렌 제이. 스피겔, 화이자 인코포레이티드 filed Critical 알렌 제이. 스피겔
Publication of KR960028907A publication Critical patent/KR960028907A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 일반명 세트랄린으로 공지된 화합물(1S-시스)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-N-메틸-1-나프탈렌아민 또는 그의 약학적으로 허용가능한 염을 인간 암 환자에게 투여함을 포함하는 상기환자의 치료 방법에 관한 것이다.

Description

암환자를 치료하기 위한 세트랄린의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 인간 암 환자에게 약 12.5㎎/일 내지 약 500㎎/일의 세트랄린 또는 그의 약학적으로 허용가능한 염을 약학적으로 허용가능한 담체 또는 부형제와 함께 투여함을 포함하는, 상기 인간 암 환자 치료를 위한 약학 조성물.
  2. 제1항에 있어서, 상기 센트랄린 또는 그의 약학적으로 혀용가능한 염을 약 25㎎/일 내지 200㎎/일의 양으로 투여하는 약학 조성물.
  3. 제1항에 있어서, 상기 세트랄린을 폐암으로 진단받은 환자에게 투여하는 약학 조성물.
  4. 제1항에 있어서, 상기 세트랄린을 췌장암으로 진단받은 환자에게 투여하는 약학 조성물.
  5. 제1항에 있어서, 상기 세트랄린을 유방암으로 진단받은 환자에게 투여하는 약학 조성물.
  6. 제1항에 있어서, 상기 세트랄린을 골암으로 진단받은 환자에게 투여하는 약학 조성물.
  7. 제1항에 있어서, 상기 세트랄린을 피부암으로 진단받은 환자에게 투여하는 약학 조성물.
  8. 제1항에 있어서, 상기 세트랄린을 호지킨 병 또는 백혈병으로 진단받은 환자에게 투여하는 약학 조성물.
  9. 제1항에 있어서, 상기 세트랄린을 위암, 직장암, 전립선암, 또는 방광암으로 진단받은 환자에게 투여하는 약학 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960000735A 1995-01-17 1996-01-16 암환자를 치료하기 위한 세트랄린의 용도 KR960028907A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37314895A 1995-01-17 1995-01-17
US08/373,148 1995-01-17

Publications (1)

Publication Number Publication Date
KR960028907A true KR960028907A (ko) 1996-08-17

Family

ID=23471181

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960000735A KR960028907A (ko) 1995-01-17 1996-01-16 암환자를 치료하기 위한 세트랄린의 용도

Country Status (9)

Country Link
EP (1) EP0727206A2 (ko)
JP (1) JPH0925230A (ko)
KR (1) KR960028907A (ko)
CN (1) CN1134279A (ko)
AU (2) AU2265695A (ko)
CA (1) CA2167257C (ko)
IL (1) IL116733A (ko)
WO (1) WO1996022085A1 (ko)
ZA (1) ZA96314B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT409084B (de) * 2000-07-13 2002-05-27 Ledochowski Maximilian Dr Antimykotisch wirkendes arzneimittel
GB0202337D0 (en) * 2002-02-01 2002-03-20 Univ Birmingham Cancer treatment
FR2849382A1 (fr) * 2002-12-26 2004-07-02 Urogene Utilisation du gene htr2b pour le traitement du cancer de la prostate
EP1656124A1 (en) * 2003-03-12 2006-05-17 Cerenis Methods and compositions for the treatment of cancer
US20060009506A1 (en) * 2004-07-09 2006-01-12 Odyssey Thera, Inc. Drugs for the treatment of neoplastic disorders
FR2888506A1 (fr) * 2005-07-12 2007-01-19 Cerenis Sa Utilisation de la 4-(3,4-dichloro-phenyl)-1,2,3,4- tetrahydro-naphtalen-1-ylamine pour le traitement du cancer
SG176571A1 (en) * 2009-05-19 2012-01-30 Vivia Biotech Sl Methods for providing personalized medicine tests ex vivo for hematological neoplasms
CN109330998A (zh) * 2018-09-19 2019-02-15 天津科技大学 一种胺盐酸盐化合物的新用途
CN112661657B (zh) * 2021-01-07 2023-07-21 中国人民解放军陆军军医大学 一种舍曲林侧链氨基结构衍生物及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596807A (en) * 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation

Also Published As

Publication number Publication date
IL116733A (en) 2000-09-28
IL116733A0 (en) 1996-05-14
EP0727206A3 (ko) 1996-08-28
AU2265695A (en) 1996-08-07
CA2167257A1 (en) 1996-07-18
CN1134279A (zh) 1996-10-30
AU4202096A (en) 1996-07-25
JPH0925230A (ja) 1997-01-28
ZA96314B (en) 1997-07-16
WO1996022085A1 (en) 1996-07-25
EP0727206A2 (en) 1996-08-21
CA2167257C (en) 1999-09-07

Similar Documents

Publication Publication Date Title
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
RU94045155A (ru) Способы ингибирования болезни альцгеймера
NO20055880L (no) Memantin orale doseringsformer
BR9712523A (pt) Novos derivados de pirazol heterociclilmetil-substituìdos
KR920019342A (ko) 골질환 치료제
AR042262A2 (es) Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis
KR960700742A (ko) 아토피성질환 치료약(atopic disease remedy)
DE69906518D1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
BR0112591A (pt) Derivados de acridina e sua aplicação como medicamento
PT97552A (pt) Processo para a preparacao de formas de dosagem para administracao de farmacos para o tratamento da doenca de parkison
TW200607511A (en) Use of optically pure (S,S)-reboxetine in the manufacture of a medicament for the treatment or prevention of peripheral neuropathy
BR0013065A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ ou ativação aberrante de leucócitos
BR0213358A (pt) Uso de flibanserina
BR9714363A (pt) Derivados de pirazol substituìdos para o tratamento de doenças circulatórias cardìacas
ES2092890T3 (es) Aplicacion del riluzol en el tratamiento de la enfermedad de parkinson y de los sindromes de parkinson.
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
KR960028907A (ko) 암환자를 치료하기 위한 세트랄린의 용도
KR970025615A (ko) 암 전이 억제제
KR970061244A (ko) 치매 치료용 약학 조성물
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
BR0013252A (pt) Micofenolato mofetila em associação com peg-ifn-alfa
PE20031047A1 (es) Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
BR9908716A (pt) Tratamento de disfunção sexual em certos grupos de pacientes

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application